TY - JOUR
T1 - Omental macrophagic “crown-like structures” are associated with poor prognosis in advanced-stage serous ovarian cancer
AU - Liang, Yu Ling
AU - Lin, Chang Ni
AU - Tsai, Hsing Fen
AU - Wu, Pei Ying
AU - Hsu, Keng Fu
AU - Lin, Sheng Hsiang
AU - Hong, Tse Ming
N1 - Funding Information:
This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 109–2314-B-006–040), partly from the Ministry of Health and Welfare (MOHW 110-TDU-B-211–144018) and the National Health Research Institutes (NHRI-110A1-CACO-02212111). We are also grateful to the Biostatistics Consulting Center, National Cheng Kung University Hospital, for providing the statistical consulting services.
Funding Information:
Acknowledgments: This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 109–2314-B-006–040), partly from the Ministry of Health and Welfare (MOHW110-TDU-B-211–144018) and the National Health Research Institutes (NHRI-110A1-CACO-02212111). We are also grateful to the Biostatistics Consulting Center, National Cheng Kung University Hospital, for providing the statistical consulting services.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10
Y1 - 2021/10
N2 - The tumor microenvironment is a well-recognized framework in which immune cells present in the tumor microenvironment promote or inhibit cancer formation and development. A crown-like structure (CLS) has been reported as a dying or dead adipocyte surrounded by a ‘crown’ of macrophages within adipose tissue, which is a histologic hallmark of the inflammatory process in this tissue. CLSs have also been found to be related to formation, progression and prognosis of some types of cancer. However, the presence of CLSs in the omentum of advanced-stage high-grade serous ovarian carcinoma (HGSOC) has not been thoroughly investigated. By using CD68, a pan-macrophage marker, and CD163, an M2-like polarization macrophage marker, immunohistochemistry (IHC) was performed to identify tumor-associated macrophages (TAMs) and CLSs. This retrospective study analyzed 116 patients with advanced-stage HGSOC who received complete treatment and had available clinical data from July 2008 through December 2016 at National Cheng Kung University Hospital (NCKUH) (Tainan, Taiwan). Based on multivariate Cox regression analysis, patients with omental CD68+ CLSs had poor OS (median survival: 24 vs. 38 months, p = 0.001, hazard ratio (HR): 2.26, 95% confidence interval (CI): 1.41–3.61); patients with omental CD163+ CLSs also had poor OS (median survival: 22 vs. 36 months, HR: 2.14, 95% CI: 1.33–3.44, p = 0.002). Additionally, patients with omental CD68+ or CD163+ CLSs showed poor PFS (median survival: 11 vs. 15 months, HR: 2.28, 95% CI: 1.43–3.64, p = 0.001; median survival: 11 vs. 15 months, HR: 2.17, 95% CI: 1.35–3.47, respectively, p = 0.001). Conversely, the density of CD68+ or CD163+ TAMs in ovarian tumors was not associated with patient prognosis in advanced-stage HGSOC in our cohort. In conclusion, we, for the first time, demonstrate that the presence of omental CLSs is associated with poor prognosis in advanced-stage HGSOC.
AB - The tumor microenvironment is a well-recognized framework in which immune cells present in the tumor microenvironment promote or inhibit cancer formation and development. A crown-like structure (CLS) has been reported as a dying or dead adipocyte surrounded by a ‘crown’ of macrophages within adipose tissue, which is a histologic hallmark of the inflammatory process in this tissue. CLSs have also been found to be related to formation, progression and prognosis of some types of cancer. However, the presence of CLSs in the omentum of advanced-stage high-grade serous ovarian carcinoma (HGSOC) has not been thoroughly investigated. By using CD68, a pan-macrophage marker, and CD163, an M2-like polarization macrophage marker, immunohistochemistry (IHC) was performed to identify tumor-associated macrophages (TAMs) and CLSs. This retrospective study analyzed 116 patients with advanced-stage HGSOC who received complete treatment and had available clinical data from July 2008 through December 2016 at National Cheng Kung University Hospital (NCKUH) (Tainan, Taiwan). Based on multivariate Cox regression analysis, patients with omental CD68+ CLSs had poor OS (median survival: 24 vs. 38 months, p = 0.001, hazard ratio (HR): 2.26, 95% confidence interval (CI): 1.41–3.61); patients with omental CD163+ CLSs also had poor OS (median survival: 22 vs. 36 months, HR: 2.14, 95% CI: 1.33–3.44, p = 0.002). Additionally, patients with omental CD68+ or CD163+ CLSs showed poor PFS (median survival: 11 vs. 15 months, HR: 2.28, 95% CI: 1.43–3.64, p = 0.001; median survival: 11 vs. 15 months, HR: 2.17, 95% CI: 1.35–3.47, respectively, p = 0.001). Conversely, the density of CD68+ or CD163+ TAMs in ovarian tumors was not associated with patient prognosis in advanced-stage HGSOC in our cohort. In conclusion, we, for the first time, demonstrate that the presence of omental CLSs is associated with poor prognosis in advanced-stage HGSOC.
UR - http://www.scopus.com/inward/record.url?scp=85117908559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117908559&partnerID=8YFLogxK
U2 - 10.3390/curroncol28050359
DO - 10.3390/curroncol28050359
M3 - Article
C2 - 34677277
AN - SCOPUS:85117908559
SN - 1198-0052
VL - 28
SP - 4234
EP - 4246
JO - Current Oncology
JF - Current Oncology
IS - 5
ER -